Liraglutide (Victoza®) has been launched for the treatment of patients with type 2 diabetes. This new drug is a glucagon-like peptide (GLP-1) analogue and is in the same class as exenatide (Byetta®).
There are slight differences between the two products in terms of the product licence. Exenatide is licensed for combination use with metformin and/or a sulphonylurea in patient not achieving adequate glycaemic control. Liraglutide is licensed in these same combinations and also in combination with metformin and a glitazone.
Exenatide has been considered in the most recent NICE Diabetes guidance but specific advice from NICE for liraglutide is not due until June 2010.
Action: Clinicians should be aware of this new drug, the licensed indications and status of the current NICE guidance.
|« Calorie restriction may prolong life||Increase in presentation of flu-like illness »|